Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With PembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, I Giacobbe et al.|Cancer Diagnosis & Prognosis|2022Cited by 28
Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathyMaria Giuseppa Vitale, Ferdinando Riccardi, Anna Crispo et al.|Frontiers in Pharmacology|2022Cited by 2
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, Carmela Barbato et al.|Annals of Oncology|2021Cited by 0
44P: First-line chemo-immunotherapy prognostic factors predicting non-small cell lung cancer (NSCLC) overall survival: Multicentric observational studyRiccardo Ronga, Ferdinando Riccardi, Fabiana Vitiello et al.|Journal of Thoracic Oncology|2025Cited by 0
EP.11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non Small Cell Lung Cancer Overall SurvivalRiccardo Ronga, Ferdinando Riccardi, Fabiana Vitiello et al.|Journal of Thoracic Oncology|2025Cited by 0